Martin Hoffmann
YOU?
Author Swipe
View article: Prospective systematic classification of causes of death in the course of multiple myeloma
Prospective systematic classification of causes of death in the course of multiple myeloma Open
View article: Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma Open
This multicenter imaging study aimed to establish and validate automated radiomics models predicting therapy response (TR) and minimal residual response (MRD) in newly diagnosed multiple myeloma (MM) from baseline MRI. Retrospectively, 118…
View article: Questioning the standard: use of ATOMS in candidates for artificial urinary sphincter therapy
Questioning the standard: use of ATOMS in candidates for artificial urinary sphincter therapy Open
View article: Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders Open
This study demonstrates that the automated detection of FLs from MRI, and thereby the automated assessment of the number of FLs, is feasible.
View article: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial Open
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT0361773…
View article: The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney Failure
The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney Failure Open
Kidney involvement with resulting kidney failure leads to increased mortality in patients with multiple myeloma (MM). Cast nephropathy (CN), in particular, if left untreated, quickly leads to kidney failure requiring dialysis and has a ver…
View article: The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network Open
View article: Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group Open
Rituximab, gemcitabine and oxaliplatin (R-GemOx) has demonstrated to be effective and safe in lymphoma patients. We aimed to determine the maximum tolerated dose (MTD) of oxaliplatin in combination with rituximab and gemcitabine and to exp…
View article: Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial Open
Bristol Myers Squibb/Celgene and Chugai.
View article: The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma - a randomized, open-label phase III trial of the European mantle cell lymphoma network Open
The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab,…
View article: Improvement of vertebral body fracture reduction utilizing a posterior reduction tool: a single-center experience
Improvement of vertebral body fracture reduction utilizing a posterior reduction tool: a single-center experience Open
View article: Horse-related injury patterns: a single center report
Horse-related injury patterns: a single center report Open
Background For ages, humankind and horses have been closely related to occupational and recreational activities. The dangers of engaging with horses have been previously reported. Among sporting activities, horse riding is well-known for i…
View article: Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an 18F-FDG PET/CT after COVID-19 Vaccination
Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an 18F-FDG PET/CT after COVID-19 Vaccination Open
Background: We aimed to evaluate the incidence of severe acute respiratory syndrome coronavirus type-2 (SARS-CoV2) vaccine-related hypermetabolic lymphadenopathy (HLA) and evaluate which time point produces the least number of false-positi…
View article: Derotational osteotomy and internal fixation of a 180° malrotated humerus: A case report
Derotational osteotomy and internal fixation of a 180° malrotated humerus: A case report Open
Single-stage radial neurolysis, derotational osteotomy and stable fixation is a feasible option to improve anatomic and functional problems of severely malrotated humeral shaft fractures.
View article: Histological Findings in Kidney Biopsies of Patients with Monoclonal Gammopathy—Always a Surprise
Histological Findings in Kidney Biopsies of Patients with Monoclonal Gammopathy—Always a Surprise Open
Background: The simultaneous occurrence of impaired kidney function and paraproteinemia is common in our constantly aging society. Both can be independent entities; however, renal insufficiency can also be caused by the paraprotein. We ass…
View article: P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL Open
Background: The multicenter phase III trial GMMG-HD7 (NCT03617731) demonstrated superior minimal residual disease (MRD) negativity rate after induction therapy in patients with transplant-eligible newly-diagnosed multiple myeloma (NDMM) by…
View article: Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age Open
View article: Monoclonal Antibodies for the Prevention and Treatment of COVID-19 Disease in Patients With Hematological Malignancies: Two Case Reports and a Literature Review
Monoclonal Antibodies for the Prevention and Treatment of COVID-19 Disease in Patients With Hematological Malignancies: Two Case Reports and a Literature Review Open
The outbreak of coronavirus disease 2019 (COVID-19) pandemic has caused worldwide problems in the care of patients with hematological malignancies. Since the first reports on the new coronavirus severe acute respiratory syndrome coronaviru…
View article: Comparison of lumbopelvic fixation and iliosacral screw fixation for the treatment of bilateral sacral fractures
Comparison of lumbopelvic fixation and iliosacral screw fixation for the treatment of bilateral sacral fractures Open
View article: Comparison of Lumbopelvic Fixation and Iliosacral Screw Fixation for the Treatment of Bilateral Sacral Fractures
Comparison of Lumbopelvic Fixation and Iliosacral Screw Fixation for the Treatment of Bilateral Sacral Fractures Open
Background: Bilateral sacral fractures result in traumatic disruption of the posterior pelvic ring. Treatment for unstable posterior pelvic ring fractures should aim for fracture reduction and rigid fixation to facilitate early mobilizatio…
View article: Navigated iliac screw placement may reduce radiation and OR time in lumbopelvic fixation of unstable complex sacral fractures
Navigated iliac screw placement may reduce radiation and OR time in lumbopelvic fixation of unstable complex sacral fractures Open
View article: Factors Associated With Major Complications and Mortality During Hospitalization in Patients With Ankylosing Spondylitis Undergoing Surgical Management for a Spine Fracture
Factors Associated With Major Complications and Mortality During Hospitalization in Patients With Ankylosing Spondylitis Undergoing Surgical Management for a Spine Fracture Open
Study design: Retrospective study. Objectives: To analyze factors associated with major complications (MC) in patients with ankylosing spondylitis (AS) undergoing surgical management for a spine fracture. Methods: Included were all persons…
View article: Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Open
View article: Aktuelle Ist-Analyse zur Situation des nichttraumatologischen Schockraummanagements in Deutschland
Aktuelle Ist-Analyse zur Situation des nichttraumatologischen Schockraummanagements in Deutschland Open
Zusammenfassung Einleitung In Notaufnahmen kommen bundesweit nichttraumatologische kritisch kranke Patienten zur Aufnahme. Zur Struktur, Organisation und Ausstattung des nichttraumatologischen Schockraummanagements ist bisher wenig bekannt…
View article: Functional outcome of traumatic spinopelvic instabilities treated with lumbopelvic fixation
Functional outcome of traumatic spinopelvic instabilities treated with lumbopelvic fixation Open
View article: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age Open
View article: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial
CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial Open
View article: Does isolated atlantoaxial fusion result in better clinical outcome compared to occipitocervical fusion?
Does isolated atlantoaxial fusion result in better clinical outcome compared to occipitocervical fusion? Open
Background The C0 to C2 region is the keystone for range of motion in the upper cervical spine. Posterior procedures usually include a fusion of at least one segment. Atlantoaxial fusion (AAF) only inhibits any motion in the C1/C2 segment …
View article: Outcome of intramedullary nailing treatment for intertrochanteric femoral fractures
Outcome of intramedullary nailing treatment for intertrochanteric femoral fractures Open
Introduction The OTA/AO type 31 A3 intertrochanteric fracture has a transverse or reverse oblique fracture at the lesser trochanteric level, which accentuates the varus compressive stress in the region of the fracture and the implant. Intr…
View article: PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY‐DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG‐MM5 TRIAL
PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY‐DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG‐MM5 TRIAL Open
Background: Analyses from prospective trials applying upfront high dose melphalan (200 mg/m 2 , HDM) and autologous blood stem cell transplantation (ASCT) up to 70 years (yrs) of age in the era of novel agents are rare. Aims: The multicent…